Edition:
India

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

66.80USD
20 Jun 2018
Change (% chg)

-- (--)
Prev Close
$66.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
170,306
52-wk High
$68.20
52-wk Low
$17.60

Chart for

About

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $1,039.60
Shares Outstanding(Mil.): 30.89
Dividend: --
Yield (%): --

Financials

BRIEF-Regenxbio Reports Q1 Earnings Per Share $3.04

* REGENXBIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

09 May 2018

BRIEF-Regenxbio Inc Q4 Loss Per Share ‍$0.51​

* REGENXBIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT OPERATIONAL HIGHLIGHTS

07 Mar 2018

BRIEF-Regenxbio Enters Strategic Partnership With Fujifilm Diosynth Biotechnologies

* REGENXBIO ENHANCES GENE THERAPY MANUFACTURING CAPABILITIES BY ENTERING INTO STRATEGIC PARTNERSHIP WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES

24 Jan 2018

BRIEF-Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments

* REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY

08 Jan 2018

BRIEF-Regenxbio Provides Year-End 2017 Corporate Update

* - ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​

05 Jan 2018

Earnings vs. Estimates